SetPoint Medical has secured $140m in private financing to accelerate the commercialisation of its SetPoint System, a neuroimmune modulation platform designed to treat rheumatoid arthritis (RA) by targeting the body’s neural pathways to regulate immune response. The device-based therapy offers a novel, non-pharmacological alternative to traditional biologics and immunosuppressants, aiming to dynamically adapt to individual disease activity.
Unlike conventional drug therapies, which can be associated with long-term safety concerns and high treatment costs, the SetPoint System engages the neuroimmune axis directly through vagus nerve stimulation, reducing proinflammatory signalling and potentially providing durable disease control. This approach positions neuroimmune modulation as a complementary, or in some cases, alternative, strategy to pharmacotherapy in autoimmune disease management.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
Graysen Vigneux, a medical analyst at GlobalData, commented: “The successful raise of $140m for SetPoint Medical reflects growing enthusiasm for neuromodulation-based therapies in autoimmune care. As treatment paradigms shift toward precision and personalisation, neuroimmune approaches offer a compelling pathway for long-term disease management.”
Neuroimmune modulation represents a rapidly emerging frontier in inflammatory disease treatment, leveraging bioelectronic medicine to control immune system activity through targeted neural circuit engagement. SetPoint’s platform builds on advances in vagus nerve stimulation technology, aligning with increasing interest in device-based solutions that offer precision without the systemic side effects of drugs.
The company intends to use the new funding to support regulatory and clinical development, scale manufacturing, expand commercial infrastructure, including reimbursement strategies and provider education, and build strategic partnerships with biopharma and healthcare organisations.
Vigneux added: “With this capital, SetPoint is well-positioned to bring its neuroimmune platform to market and catalyse broader acceptance of bioelectronic medicine in autoimmune disease treatment.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe financing underscores strong investor confidence in neuromodulation as a transformative approach for autoimmune conditions. By advancing both regulatory and go-to-market strategies, SetPoint aims to make its neuroimmune therapy widely accessible, potentially reshaping the RA treatment landscape with a durable, device-based solution.
